What women's health problems are underserved?

This blog post has been written by the person who has mapped the women's health market in a clean and beautiful presentation

The women's health market presents massive untapped opportunities, with endometriosis, PCOS, and menopause care receiving disproportionately low funding despite affecting hundreds of millions of women globally.

With 190 million women suffering from endometriosis and facing 10-year diagnostic delays, while 65.8 million live with PCOS and over 1 billion women will reach menopause by 2025, the investment gap represents a trillion-dollar opportunity for entrepreneurs and investors ready to tackle these underserved conditions.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What specific areas of women's health have received the least venture capital and government funding in the past 5 years?

Endometriosis, PCOS, and menopause care represent the most critically underfunded areas despite affecting hundreds of millions of women globally.

Endometriosis affects 190 million women worldwide with 3 million new diagnoses annually, yet receives minimal venture capital attention relative to its burden. The condition faces an average 10-year diagnostic delay, creating massive opportunities for non-invasive screening technologies and targeted therapeutic approaches that current healthcare systems fail to provide.

PCOS affects 65.8 million women globally and shows rising prevalence, particularly in developing regions where lifestyle factors compound the condition. Despite representing a clear market need for integrated lifestyle, metabolic, and fertility management solutions, PCOS-focused startups receive disproportionately low funding compared to other chronic conditions affecting similar population sizes.

Menopause care funding remains shockingly inadequate given that over 1 billion women will reach menopause by 2025, driving a market projected to reach $24.35 billion by 2030 with a 5.4% CAGR. Current solutions lack data-driven personalization for symptom management, hormone replacement therapy optimization, and comprehensive support systems that address the full spectrum of menopausal health needs.

Women's cardiovascular health and autoimmune conditions also suffer from significant funding gaps, with sex-specific research remaining limited despite cardiovascular disease being the leading cause of death among women and autoimmune conditions affecting women at rates 2-3 times higher than men.

Which women's health conditions have the highest patient population growth but lack innovative solutions as of 2025?

PCOS shows the most dramatic patient population growth trajectory while simultaneously lacking proportionate innovative solutions to address its complex, multi-system impact.

The global PCOS burden continues expanding rapidly, particularly in South Asia and sub-Saharan Africa where urbanization and dietary transitions compound genetic predispositions. Current treatment approaches remain fragmented across endocrinology, gynecology, and dermatology, with no integrated platforms addressing the condition's metabolic, reproductive, and psychological dimensions comprehensively.

Endometriosis diagnoses are accelerating as awareness campaigns reduce stigma and encourage medical consultations, yet diagnostic innovations remain virtually non-existent. The 10-year average delay from symptom onset to diagnosis represents a massive market failure that entrepreneurs could address through point-of-care biomarkers, advanced imaging techniques, or AI-powered symptom pattern recognition systems.

Perimenopause and menopause populations surge as global demographics shift, with baby boomer cohorts entering menopause while life expectancy extends post-menopausal years. Despite this demographic wave, innovation focuses primarily on hormone replacement therapy rather than comprehensive lifestyle management, cognitive health preservation, or bone density optimization that women actually prioritize.

Mental health conditions among women, including perinatal depression and anxiety, show concerning growth patterns yet receive minimal targeted innovation beyond traditional psychiatric approaches, creating opportunities for gender-specific digital therapeutics and hormonal-aware treatment protocols.

If you want to build on this market, you can download our latest market pitch deck here

What are the most common complaints or unmet needs from women patients that current healthcare systems fail to address?

Medical dismissal and symptom normalization represent the most pervasive complaints, with two-thirds of women reporting their symptoms labeled as "emotional" or dismissed as "just part of being a woman."

Fragmented care pathways frustrate women managing chronic conditions who require coordination across multiple specialties but instead navigate disconnected systems with poor communication between providers. Women with endometriosis, for example, typically consult gynecologists, pain specialists, and mental health professionals without integrated treatment planning or shared electronic health records that could optimize outcomes.

Cost-related care delays affect 35% of U.S. women who postpone or skip women's health visits due to perceived low value or financial constraints. This creates opportunities for value-based care models, transparent pricing structures, and preventive care platforms that demonstrate clear health and economic benefits to patients and payers.

Information accessibility gaps persist despite digital health proliferation, with women struggling to access reliable, personalized health information that accounts for their specific life stages, cultural backgrounds, and health conditions. Current patient education materials remain generic and fail to address the nuanced questions women have about hormonal fluctuations, reproductive health decisions, and aging-related changes.

Long-term relationship continuity with healthcare providers remains elusive, particularly for reproductive health where women frequently change providers due to insurance limitations, geographic moves, or provider availability, disrupting the ongoing relationships essential for managing complex women's health conditions effectively.

Which demographics of women are most underserved in terms of access to diagnosis, treatment, or follow-up?

Rural women face the most severe access barriers, experiencing longer travel distances to specialists, fewer available providers, and significant insurance coverage gaps that compound geographic isolation.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

What recent regulatory or reimbursement changes in 2025 have impacted innovation or investment in women's health?

The FDA's 2025 approvals significantly expanded access to women's health innovations, with four groundbreaking approvals transforming diagnostic and treatment landscapes.

Gepotidacin approval marked the first new antibiotic class for uncomplicated urinary tract infections in decades, addressing a critical need affecting millions of women annually. The Visby at-home STI test kit approval revolutionized sexual health screening by enabling private, rapid testing outside clinical settings, reducing barriers that previously prevented many women from accessing regular STI screening.

The Teal Wand's FDA clearance for self-collection cervical screening represents a paradigm shift toward patient-controlled preventive care, potentially improving screening rates among women who avoid traditional pelvic examinations due to trauma, cultural reasons, or access barriers. Sonio Suspect AI's approval for fetal anomaly detection demonstrates growing regulatory acceptance of AI-powered diagnostic tools in women's health.

Reimbursement improvements expanded significantly, with Australia's Pharmaceutical Benefits Scheme adding new menopause hormone therapies and long-acting reversible contraceptives to national formularies. These coverage expansions signal growing recognition of women's health as a reimbursement priority, encouraging further innovation investment by reducing market access risks for developers.

International regulatory harmonization efforts in 2025 created clearer pathways for women's health devices and digital therapeutics across multiple markets, reducing regulatory uncertainty that previously deterred investment in innovative solutions targeting global women's health needs.

Which startups or products launched in 2024-2025 are gaining early traction in underserved segments of women's health?

Comanche Bio leads the emerging preeclampsia treatment space with $75 million Series A funding, addressing a condition affecting 5-8% of pregnancies worldwide with limited therapeutic options.

If you want clear data about this market, you can download our latest market pitch deck here

What are the top 3 women's health issues projected to grow fastest in demand by 2026 and over the next 5 years?

Menopause care leads projected demand growth with over 1 billion women reaching menopause by 2025, driving unprecedented need for comprehensive symptom management and hormonal health optimization.

The demographic surge of baby boomers entering menopause, combined with increased longevity extending post-menopausal life phases, creates massive market opportunities for personalized hormone replacement therapy, cognitive health preservation, and bone density management solutions. Current approaches remain fragmented and one-size-fits-all, leaving enormous room for data-driven, personalized interventions that address individual symptom profiles and health goals.

PCOS management ranks second in projected growth, with 65.8 million prevalent cases globally and rising incidence rates driven by urbanization and lifestyle factors in developing markets. The condition's complex multi-system impact requires integrated solutions addressing metabolic dysfunction, reproductive health, and psychological wellbeing simultaneously, yet current treatment remains siloed across medical specialties.

Endometriosis diagnostics and treatment represents the third fastest-growing demand area, fueled by increased awareness campaigns reducing stigma and encouraging medical consultation. With 190 million women affected globally and average diagnostic delays of 10 years, the market opportunity for non-invasive screening technologies and targeted therapeutic approaches remains virtually untapped by current healthcare systems.

Secondary growth areas include women's cardiovascular health as awareness of sex-specific risk factors increases, and maternal mental health as perinatal depression recognition improves through screening program expansion and stigma reduction efforts worldwide.

How are digital health, telemedicine, or AI tools currently underleveraged in women's health care?

Telemedicine adoption remains limited at 60% despite 69% of women rating virtual care as equivalent to in-person visits, indicating massive untapped potential for routine women's health services.

AI diagnostic applications show promising early results but remain concentrated in narrow areas like fetal anomaly detection and STI screening, while broader applications for endometriosis pattern recognition, PCOS metabolic profiling, and menopause symptom management remain largely unexplored by commercial developers.

Data-driven personalization represents the most significant underutilized opportunity, with hormonal cycle tracking, wearable device integration, and predictive analytics for fertility, menopause, and chronic pain management showing potential but lacking comprehensive platforms that synthesize multiple data sources into actionable health insights for women.

Remote monitoring capabilities remain underdeveloped for pregnancy care beyond basic vitals tracking, missing opportunities for early preeclampsia detection, gestational diabetes management, and mental health screening that could significantly improve maternal and fetal outcomes while reducing healthcare costs.

Cultural competency in digital health tools remains minimal, with most platforms failing to address diverse cultural attitudes toward reproductive health, family planning, and women's healthcare decision-making that could improve adoption rates among underserved demographic groups globally.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Which areas of women's reproductive, hormonal, or chronic health still lack personalized or data-driven solutions?

Hormonal health optimization across the entire female lifespan lacks integrated, data-driven platforms that account for individual genetic profiles, lifestyle factors, and symptom patterns to deliver personalized interventions.

Current hormone replacement therapy approaches remain largely standardized despite significant individual variation in metabolism, receptor sensitivity, and symptom presentation. Opportunities exist for pharmacogenomic testing, continuous hormone monitoring, and AI-powered dosing optimization that could dramatically improve outcomes while reducing side effects for millions of menopausal women.

Chronic pelvic pain management suffers from a complete absence of personalized diagnostic and therapeutic approaches, despite affecting up to 20% of women and showing significant heterogeneity in underlying causes, pain patterns, and treatment responses. Digital therapeutics combining cognitive behavioral therapy, pelvic floor exercises, and pain tracking could provide personalized interventions currently unavailable through traditional healthcare.

Fertility optimization beyond basic cycle tracking remains primitive, with most platforms failing to integrate comprehensive health data including stress markers, sleep patterns, nutritional status, and environmental factors that significantly impact reproductive success. Advanced predictive modeling could identify optimal conception timing and intervention strategies personalized to individual fertility profiles.

Autoimmune condition management in women lacks sex-specific treatment protocols despite women representing 75% of autoimmune patients and showing different disease progression patterns, medication responses, and flare triggers compared to men, creating opportunities for gender-specific therapeutic approaches.

If you want to build or invest on this market, you can download our latest market pitch deck here

What has been the feedback from clinicians and practitioners about gaps in women-specific diagnostic tools or treatments?

Clinicians consistently report frustration with diagnostic delays for endometriosis, citing the absence of reliable non-invasive biomarkers or imaging techniques that could reduce the current average 10-year delay from symptom onset to definitive diagnosis.

Pain assessment tools remain inadequate for women's health conditions, with current pain scales failing to capture the cyclical, hormonal, and multidimensional nature of conditions like endometriosis, chronic pelvic pain, and menstrual disorders. Practitioners emphasize the need for validated, women-specific pain assessment instruments that account for hormonal fluctuations and chronic pain adaptation patterns.

PCOS diagnostic criteria create significant practitioner challenges, with current guidelines requiring complex combinations of clinical, biochemical, and imaging findings that often delay diagnosis and treatment initiation. Clinicians advocate for streamlined diagnostic algorithms and point-of-care testing that could accelerate identification and intervention for this common but underdiagnosed condition.

Cardiovascular risk assessment tools systematically underestimate women's risk by relying on male-derived algorithms, leading to delayed diagnosis and suboptimal treatment of heart disease in women. Practitioners urgently need sex-specific risk calculators and diagnostic criteria that account for women's unique presentation patterns and risk factors.

Mental health screening in reproductive health settings remains inadequate, with practitioners lacking validated tools for detecting perinatal depression, anxiety, and other mood disorders that require specialized intervention approaches different from general mental health screening protocols.

How do cultural taboos or stigma around women's health issues create market inefficiencies?

Menstruation-related stigma creates massive market inefficiencies by preventing open discussion of period problems, delaying endometriosis and PCOS diagnoses, and limiting market research for menstrual health innovations.

Cultural taboos surrounding sexual health prevent many women from seeking STI testing, contraceptive counseling, and sexual dysfunction treatment, creating underutilized healthcare capacity and unmet market demand for discrete, culturally sensitive solutions. These barriers particularly impact immigrant communities and conservative regions where traditional gender roles discourage women's health advocacy.

Menopause stigma in many cultures frames natural hormonal transitions as weakness or decline, preventing women from seeking treatment for debilitating symptoms and limiting market development for menopause management solutions. This cultural barrier creates artificial scarcity in markets where demographic trends should drive robust demand for menopause care innovations.

Mental health stigma compounds women's health challenges by preventing discussion of perinatal depression, anxiety disorders, and psychological impacts of chronic conditions like infertility or chronic pain. This stigma creates market inefficiencies by limiting demand expression for integrated mental health solutions within women's healthcare platforms.

Body image and weight stigma prevent many women from seeking preventive care and discussing symptoms related to PCOS, eating disorders, and metabolic health, creating missed opportunities for early intervention and comprehensive care management that could improve outcomes and reduce long-term healthcare costs.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

What are the most promising white spaces in the women's health market where no dominant players currently exist?

Non-invasive endometriosis screening represents the most significant white space opportunity, with no established players offering reliable point-of-care biomarkers or imaging technologies that could eliminate the current 10-year diagnostic delay affecting 190 million women globally.

Integrated hormonal health platforms spanning puberty through post-menopause lack dominant market players, creating opportunities for comprehensive solutions that combine wearable data, genetic testing, and personalized interventions across the entire female hormonal lifespan rather than addressing isolated life stages.

Women's cardiometabolic health solutions remain fragmented across general cardiology and endocrinology, with no specialized platforms addressing sex-specific risk factors, presentation patterns, and treatment responses that differentiate women's cardiovascular and metabolic health needs from male-focused approaches.

Chronic pelvic pain digital therapeutics represent a completely open market space, with no established players offering evidence-based digital interventions combining pain psychology, pelvic floor rehabilitation, and lifestyle modifications tailored to the complex, multifactorial nature of women's chronic pain conditions.

Culturally competent women's health platforms remain absent from most markets, creating opportunities for solutions that address diverse cultural attitudes toward reproductive health, family planning, and medical decision-making that could significantly improve adoption among underserved global populations.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Conclusion

Sources

1. World Economic Forum - Women Healthcare Gap
2. Nature - Women's Health Research
3. McKinsey - Closing the Women's Health Gap
4. Frontiers in Public Health - PCOS Global Burden
5. Grand View Research - Menopause Market
6. Deloitte - Why Women Skip Healthcare
7. KFF - Women's Health Survey
8. Contemporary OB/GYN - FDA Approvals 2025
9. BioPharma Dive - Women's Health Venture Funding
10. Everything Startups - Femtech Funding April 2025
11. Silicon Valley Bank - Women's Health Report
12. WHO - Endometriosis Fact Sheet
13. WHO - PCOS Fact Sheet
14. ACOG - Health Disparities in Rural Women
15. RACGP - Women's Health Funding Australia